- Home
- STEP vs INDV Comparison
STEP vs INDV Comparison
Compare STEP & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STEP | INDV |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 3.7B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | STEP | INDV |
|---|---|---|
| Price | $54.71 | $32.54 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $73.13 | N/A |
| AVG Volume (30 Days) | 876.1K | ★ 2.2M |
| Earning Date | 05-21-2026 | 06-08-2026 |
| Dividend Yield | ★ 2.89% | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | N/A | ★ 1.64 |
| Revenue | $1,174,830,000.00 | ★ $1,239,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $28.87 | N/A |
| P/E Ratio | ★ N/A | $20.09 |
| Revenue Growth | ★ 65.09 | 4.29 |
| 52 Week Low | $40.58 | $8.69 |
| 52 Week High | $77.80 | $38.00 |
Technical Indicators
Market Signals| Indicator | STEP | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 67.21 | 55.14 |
| Support Level | $44.48 | $31.70 |
| Resistance Level | $63.93 | $32.42 |
| Average True Range (ATR) | 2.35 | 1.18 |
| MACD | 1.11 | 0.39 |
| Stochastic Oscillator | 92.88 | 73.89 |
Price Performance
Historical ComparisonAbout STEP StepStone Group Inc.
StepStone Group Inc operates as a fully integrated private markets solution provider. The company provides customized investment solutions and advisory and data services. It provides investment solutions in the areas of private equity, real estate, private debt, and infrastructure and real assets. The company consists of a single operating segment and a single reportable segment for accounting and financial reporting purposes.
About INDV Indivior PLC
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).